US04280A1007 - Common Stock
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the third quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arrowhead Pharma (NASDAQ:ARWR) just reported results for the third quarter of 2...
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Low priced stocks to buy for growth provide great value to investors in the $20 range and are expected to pop before 2025.